Arnon Rosenthal received his PhD from the Hebrew University Jerusalem, Israel, and then conducted a postdoctoral fellowship at Genentech, Inc. Following his postdoc, he was appointed to a scientist position at Genentech, Inc., and was later promoted to a senior scientist then to staff scientist and permanent member of Genentech Research Review Committee.

Dr. Rosenthal is co-founder of Rinat Neuroscience, a privately held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders, where he also served as President, board member and CSO. Rinat was acquired by Pfizer with several drugs in clinical development, including Tanezumab which is currently in Phase 3 for multiple pain indications, PF-04360365, which entered Phase 2 for Alzheimer’s disease, and RN-307 which entered the clinic for migraine.

Dr. Rosenthal is also co-founder, President and CEO of Alector LLC, a privately held biotechnology company focused on the discovery and development of novel therapies for Alzheimer’s disease and other forms of dementia. Dr. Rosenthal is a visiting professor of the Department of Anatomy at the University of California San Francisco and a member of the scientific advisory boards of Simons Foundation, Autism Research Initiative, and the Myelin Repair Foundation. He has co-authored 108 scientific publications and more than 380 issued patents and applications.